Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration

[1]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[2]  O. Della Pasqua,et al.  The implications of model-informed drug discovery and development for tuberculosis. , 2017, Drug discovery today.

[3]  A. Diacon,et al.  High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial , 2017, The Lancet. Infectious diseases.

[4]  M. Pagano,et al.  Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial , 2016, BMC Infectious Diseases.

[5]  Matthew D. Zimmerman,et al.  The association between sterilizing activity and drug distribution into tuberculosis lesions , 2015, Nature Medicine.

[6]  K. Romero,et al.  Nonclinical models for antituberculosis drug development: a landscape analysis. , 2015, The Journal of infectious diseases.

[7]  D. Mitchison,et al.  The early bactericidal activity of drugs in patients with pulmonary tuberculosis. , 2015, The American review of respiratory disease.

[8]  A. Diacon,et al.  A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. , 2015, American journal of respiratory and critical care medicine.

[9]  S. Waddell,et al.  Understanding anti-tuberculosis drug efficacy: rethinking bacterial populations and how we model them. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[10]  Wonsik Lee,et al.  Novel Inhibitors of Cholesterol Degradation in Mycobacterium tuberculosis Reveal How the Bacterium’s Metabolism Is Constrained by the Intracellular Environment , 2015, PLoS pathogens.

[11]  Philip Greulich,et al.  Growth‐dependent bacterial susceptibility to ribosome‐targeting antibiotics , 2014, Molecular systems biology.

[12]  A. Crook,et al.  Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. , 2014, The New England journal of medicine.

[13]  L. Rigouts,et al.  Standardization of a TaqMan-based real-time PCR for the detection of Mycobacterium tuberculosis-complex in human sputum. , 2014, The American journal of tropical medicine and hygiene.

[14]  D. Schnappinger,et al.  Triosephosphate Isomerase Is Dispensable In Vitro yet Essential for Mycobacterium tuberculosis To Establish Infection , 2014, mBio.

[15]  B. Genton,et al.  A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.

[16]  I. Ulus,et al.  Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[17]  T. Hwa,et al.  Coordination of bacterial proteome with metabolism by cyclic AMP signalling , 2013, Nature.

[18]  N. Balaban,et al.  A problem of persistence: still more questions than answers? , 2013, Nature Reviews Microbiology.

[19]  J. Perfect,et al.  Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. , 2013, The Journal of infectious diseases.

[20]  E. Rubin,et al.  Feast or famine: the host–pathogen battle over amino acids , 2013, Cellular microbiology.

[21]  R. Donders,et al.  Isoniazid, Rifampin, and Pyrazinamide Plasma Concentrations in Relation to Treatment Response in Indonesian Pulmonary Tuberculosis Patients , 2013, Antimicrobial Agents and Chemotherapy.

[22]  G. Kibiki,et al.  Pharmacokinetics of First-Line Tuberculosis Drugs in Tanzanian Patients , 2013, Antimicrobial Agents and Chemotherapy.

[23]  Mehmet A. Orman,et al.  Dormancy Is Not Necessary or Sufficient for Bacterial Persistence , 2013, Antimicrobial Agents and Chemotherapy.

[24]  T. Rito,et al.  Antitubercular pharmacodynamics of phenothiazines. , 2013, The Journal of antimicrobial chemotherapy.

[25]  Lin Zhou,et al.  Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers. , 2013, Clinical therapeutics.

[26]  Stanislas Leibler,et al.  Dynamic Persistence of Antibiotic-Stressed Mycobacteria , 2013, Science.

[27]  K. Rodvold,et al.  Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid , 2011, Clinical pharmacokinetics.

[28]  H. McIlleron,et al.  Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. , 2011, British journal of clinical pharmacology.

[29]  Siv Jönsson,et al.  Population Pharmacokinetics of Ethambutol in South African Tuberculosis Patients , 2011, Antimicrobial Agents and Chemotherapy.

[30]  R. Basaraba,et al.  Location of Intra- and Extracellular M. tuberculosis Populations in Lungs of Mice and Guinea Pigs during Disease Progression and after Drug Treatment , 2011, PloS one.

[31]  A. van Belkum,et al.  Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. , 2010, The Journal of antimicrobial chemotherapy.

[32]  T. Hwa,et al.  Interdependence of Cell Growth and Gene Expression: Origins and Consequences , 2010, Science.

[33]  A. Genovesio,et al.  High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling , 2010, PLoS pathogens.

[34]  K. Kuhen,et al.  A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy , 2010, Nature Communications.

[35]  G. Davies.  Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity. , 2010, Tuberculosis.

[36]  J. Flynn,et al.  The spectrum of latent tuberculosis: rethinking the biology and intervention strategies , 2009, Nature Reviews Microbiology.

[37]  Stewart T. Cole,et al.  High Content Screening Identifies Decaprenyl-Phosphoribose 2′ Epimerase as a Target for Intracellular Antimycobacterial Inhibitors , 2009, PLoS pathogens.

[38]  A. Benedetti,et al.  Effect of Duration and Intermittency of Rifampin on Tuberculosis Treatment Outcomes: A Systematic Review and Meta-Analysis , 2009, PLoS medicine.

[39]  M. Perkins,et al.  Confronting the scientific obstacles to global control of tuberculosis. , 2008, The Journal of clinical investigation.

[40]  D. Mitchison,et al.  A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[41]  D. Sherman,et al.  Identification of Mycobacterial genes that alter growth and pathology in macrophages and in mice. , 2007, The Journal of infectious diseases.

[42]  A. Diacon,et al.  Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum Smears , 2007, Antimicrobial Agents and Chemotherapy.

[43]  S. Khoo,et al.  Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. , 2007, Tuberculosis.

[44]  V. Mizrahi,et al.  The survival kit of Mycobacterium tuberculosis , 2007, Nature Medicine.

[45]  L. Aarons,et al.  Use of Nonlinear Mixed-Effects Analysis for Improved Precision of Early Pharmacodynamic Measures in Tuberculosis Treatment , 2006, Antimicrobial Agents and Chemotherapy.

[46]  E. Muñoz-Elías,et al.  Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence , 2006, Molecular microbiology.

[47]  H. McIlleron,et al.  Determinants of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol Pharmacokinetics in a Cohort of Tuberculosis Patients , 2006, Antimicrobial Agents and Chemotherapy.

[48]  S. Rosenkranz,et al.  The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  R. Chaisson,et al.  Erratum: Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis (American Journal of Respiratory and Critical Care Medicine (2004) 169 (421-426)) , 2005 .

[50]  R. Chaisson,et al.  Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. , 2004, American journal of respiratory and critical care medicine.

[51]  R. Chaisson,et al.  Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. , 2004, American journal of respiratory and critical care medicine.

[52]  C. Doré,et al.  Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. , 2003, American journal of respiratory and critical care medicine.

[53]  J. Grosset.  Mycobacterium tuberculosis in the Extracellular Compartment: an Underestimated Adversary , 2003, Antimicrobial Agents and Chemotherapy.

[54]  D. Mitchison,et al.  Sterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.

[55]  James C. Sacchettini,et al.  Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase , 2000, Nature.

[56]  D. Mitchison,et al.  A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. , 2000, The Journal of antimicrobial chemotherapy.

[57]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[58]  R. Jelliffe,et al.  Pharmacokinetics of Ethambutol under Fasting Conditions, with Food, and with Antacids , 1999, Antimicrobial Agents and Chemotherapy.

[59]  R. Jelliffe,et al.  Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide , 1997, Antimicrobial agents and chemotherapy.

[60]  M. R. Brown,et al.  Influence of growth rate on susceptibility to antimicrobial agents: modification of the cell envelope and batch and continuous culture studies , 1990, Antimicrobial Agents and Chemotherapy.

[61]  M. Felten.  Importance of rifampicin in combined daily/intermittent chemotherapy for tuberculosis. , 1989, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[62]  H. El-Attar,et al.  Pharmacokinetics of Antituberculosis Drugs in Patients , 1987, Journal of clinical pharmacology.

[63]  A. Tomasz,et al.  The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth. , 1986, Journal of general microbiology.

[64]  M. Eichelbaum,et al.  Pharmacokinetics of oral and intravenous rifampicin during chronic administration , 1985, Klinische Wochenschrift.

[65]  D. Mitchison.  Basic mechanisms of chemotherapy. , 1979, Chest.

[66]  L. Benet,et al.  Kinetics of oral ethambutol in the normal subject , 1977, Clinical pharmacology and therapeutics.

[67]  J. Mao,et al.  Local infiltration with cocktail analgesics during 2 level lumbar spinal fusion surgery , 2019, Medicine.

[68]  Clifton E. Barry,et al.  Tuberculosis — metabolism and respiration in the absence of growth , 2005, Nature Reviews Microbiology.

[69]  M. Bourin,et al.  Pharmacokinetics of isoniazid: Influence of age , 2004, European Journal of Clinical Pharmacology.